ENOV on NYSE

Colfax Corporation

American medical technology company

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV.3 It was founded by Mitchell Rales.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1995Founded1

Compare with MSA Safety, Align Technology or Bone Biologics Corp, or pick any stock.

  • TickerENOV on NYSE1
  • Industrymedical technology1
  • HeadquartersAnnapolis Junction1
  • Websitewww.colfaxcorp.com
  • Legal formDelaware corporation1
  • Incorporated inDE5
  • Business address2900 Lake Vista Drive, Suite 200, Lewisville, Tx 750675
  • Filer categoryLarge accelerated filer5
  • LEI635400OP2DYYYMOIYL174
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressCORPORATION TRUST CENTER, 19801 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 28637694

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV. The company has over 8,000 employees operating at 30 sites around the world.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.8%Gross margin9
-50.0%Operating margin9
-52.7%Net margin9
6.7%Revenue growth, 20259
-79.5%Return on equity9
0.85×Debt to equity9
$19.9MFree cash flow9

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue40¢$902.8M
  • Research and development5¢$120.3M
  • Selling, general and admin48¢$1.1B
  • Other costs4¢$97.7M
  • Interest2¢$34.8M
  • Income tax1¢$22.3M

Out of $2.2B in revenue.9 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending91¢$197.4M
  • Share buybacks2¢$3.5M
  • Kept or used elsewhere8¢$16.4M

Out of $217.3M of cash from operations.9

Financial statements

Revenue101112139$2.2B in 2025−32% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $3.3B$3.3B20192020: $1.1B$1.1B2020−66%2021: $1.4B$1.4B2021+27%2022: $1.6B$1.6B2022+10%2023: $1.7B$1.7B2023+9%2024: $2.1B$2.1B2024+23%2025: $2.2B$2.2B2025+7%
Gross profit101112139$1.3B in 2025−4% since 2019
0$500.0M$1.0B$1.5B2019: $1.4B$1.4B20192020: $603.6M$603.6M2020−57%2021: $777.7M$777.7M2021+29%2022: $869.4M$869.4M2022+12%2023: $990.8M$990.8M2023+14%2024: $1.2B$1.2B2024+19%2025: $1.3B$1.3B2025+14%
Operating income101112139-$1.1B in 2025
-$1.5B-$1.0B-$500.0M0$500.0M2019: $203.6M$203.6M20192020: -$66.2M-$66.2M20202021: -$62.8M-$62.8M2021−5%2022: -$71.2M-$71.2M2022+13%2023: -$65.7M-$65.7M2023−8%2024: -$775.7M-$775.7M2024+1081%2025: -$1.1B-$1.1B2025+45%
Net income101112139-$1.2B in 2025+124% since 2019
-$1.5B-$1.0B-$500.0M0$500.0M2019: -$527.6M-$527.6M20192020: $42.6M$42.6M20202021: $71.7M$71.7M2021+68%2022: -$13.3M-$13.3M20222023: -$33.3M-$33.3M2023+150%2024: -$825.5M-$825.5M2024+2382%2025: -$1.2B-$1.2B2025+43%
Fiscal year2019202020212022202320242025
Revenue$3.3B10$1.1B11$1.4B12$1.6B13$1.7B9$2.1B9$2.2B9
Cost of revenue$1.9B10$517.1M11$648.5M12$693.7M13$716.4M9$926.9M9$902.8M9
Gross profit$1.4B10$603.6M11$777.7M12$869.4M13$990.8M9$1.2B9$1.3B9
Research and development$34.3M11$49.1M12$60.8M13$75.3M9$91.3M9$120.3M9
Selling, general and admin$1.1B10$515.5M11$665.8M12$772.9M13$830.3M9$1.0B9$1.1B9
Operating income$203.6M10-$66.2M11-$62.8M12-$71.2M13-$65.7M9-$775.7M9-$1.1B9
Interest$119.5M10$52.8M11$29.1M12$24.1M13$19.7M9$57.1M9$34.8M9
Income before tax-$121.8M12-$2.1M13-$67.1M9-$822.9M9-$1.2B9
Income tax$31.6M10-$44.6M11-$19.5M12$36.1M13-$13.3M9$4.5M9$22.3M9
Net income-$527.6M10$42.6M11$71.7M12-$13.3M13-$33.3M9-$825.5M9-$1.2B9
Earnings per share-$3.8910$0.9311$1.4012-$0.2513-$0.619-$14.939-$20.759
Earnings per share (diluted)-$3.8910$0.9311$1.4012-$0.2513-$0.619-$14.939-$20.759
Shares (weighted, basic)51.1M shares1254.1M shares1354.5M shares955.3M shares957.1M shares9
Shares (weighted, diluted)51.1M shares1254.1M shares1354.5M shares955.3M shares957.1M shares9

Compare Colfax Corporation with another company

Corporate structure

Colfax Corporation sits at the top of its group. 233 entities, 52 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Colfax Corporation

  • Colfax Corporation Wilmington, Delaware, United States
    • ESAB Fulton, Maryland, United States
      • 9559-2796 Québec Inc. Subsidiary · Canada
      • Aktiv Technologies Pvt. Ltd. Subsidiary · India
      • Bavaria Schweisstechnik GmbH Subsidiary · Germany
      • CAST Limited Subsidiary · United Kingdom
      • Central Mining Finance Limited Subsidiary · United Kingdom
      • Charter Central Finance Limited Subsidiary · United Kingdom
      • Charter Central Services Limited Subsidiary · United Kingdom
      • Charter Consolidated Holdings Limited Subsidiary · United Kingdom
      • Charter Consolidated Limited Subsidiary · United Kingdom
      • Charter International Limited Subsidiary · Jersey
      • Charter Limited Subsidiary · United Kingdom
      • Charter Pension Trustee Limited Subsidiary · United Kingdom
      • Cigweld Pty Ltd. Subsidiary · Australia
      • Colfax Jersey Finance Limited Subsidiary · Jersey
      • Colfax UK Holdings Limited Subsidiary · United Kingdom
      • Comercializadora Thermadyne S. de R.L. de C.V. Subsidiary · Mexico
      • Conarco Alambres y Soldaduras SA Subsidiary · Argentina
      • Condor Equipamentos Industriais Ltda Subsidiary · Brazil
      • Delta P s.r.l. Subsidiary · Italy
      • ESAB Africa Welding and Cutting (Proprietary) Limited Subsidiary · South Africa
      • ESAB ApS Subsidiary · Denmark
      • ESAB Arabia Company Limited Subsidiary · Saudi Arabia
      • ESAB Bangladesh Private Limited Subsidiary · Bangladesh
      • ESAB Bulgaria EAD Subsidiary · Bulgaria
      • ESAB Chile SPA Subsidiary · Chile
      • and 108 more
    • Howden ČKD Compressors Subsidiary · Praha, Czechia
    • "ESAB" SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ Subsidiary · Fulton, Maryland, United States
    • Armac, Inc. Subsidiary · New Jersey, United States
    • Athena Finance Limited Subsidiary · Barbados
    • Cefar-Compex Medical AB Subsidiary · Sweden
    • Chattanooga Europe, B.V. Subsidiary · Belgium
    • Colfax (Wuxi) Pump Company Limited Subsidiary · China
    • Colfax Group GmbH Subsidiary · Germany
    • DJ Orthopedics de Mexico, S.A. de C.V. Subsidiary · Mexico
    • DJ Orthopedics Services, SA de CV Subsidiary · Mexico
    • DJO Asia-Pacific Ltd. Subsidiary · Hong Kong
    • DJO Benelux B.V. Subsidiary · Belgium
    • DJO Brasil Ltda. Subsidiary · Brazil
    • DJO Canada Inc. Subsidiary · Canada
    • DJO Consumer, LLC Subsidiary · Delaware, United States
    • DJO Finance LLC Subsidiary · Delaware, United States
    • DJO France S.A.S. Subsidiary · France
    • DJO Global India Healthcare Private Limited Subsidiary · India
    • DJO Global Pty Ltd Subsidiary · Australia
    • DJO Global Switzerland SARL Subsidiary · Switzerland
    • DJO Iberica Productos Ortopedicos S.L. Subsidiary · Spain
    • DJO Italia SRL Subsidiary · Italy
    • DJO Medical Device Trading (Shanghai) Ltd. Subsidiary · China
    • DJO Nordic Aktiebolag Subsidiary · Sweden
    • and 73 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Colfax Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$903.9M9 Dec 31, 2025$724.0M9 Dec 31, 2024+24.8%
Accumulated depreciation$396.8M9 Dec 31, 2025$319.5M9 Dec 31, 2024+24.2%
Property and equipment, net$507.1M9 Dec 31, 2025$404.5M9 Dec 31, 2024+25.4%
Operating-lease assets (leased space)$72.3M9 Dec 31, 2025$68.9M9 Dec 31, 2024+4.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$36.4M9 Dec 31, 2025$48.2M9 Dec 31, 2024−24.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$718.3M9 Dec 31, 2025$1.7B9 Dec 31, 2024−57.6%
Intangible assets, net (excluding goodwill)$1.2B9 Dec 31, 2025$1.3B9 Dec 31, 2024−6.1%
Accumulated amortization$940.3M9 Dec 31, 2025$773.7M9 Dec 31, 2024+21.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$584.4M9 Dec 31, 2025$547.1M9 Dec 31, 2024+6.8%
Raw materials$120.6M9 Dec 31, 2025$99.6M9 Dec 31, 2024+21.1%
Work in process$54.9M9 Dec 31, 2025$50.0M9 Dec 31, 2024+9.8%
Finished goods$497.6M9 Dec 31, 2025$483.6M9 Dec 31, 2024+2.9%

Properties, in its own words

Our corporate headquarters are located in Wilmington, Delaware in a facility that we lease.

As of December 31, 2025, our Prevention & Recovery segment had a total of five facilities used in production, distribution and warehousing in the U.S., representing a total 241,000 square feet of leased space and eleven facilities used in production, distribution and warehousing outside the U.S., representing a total of 925,000 square feet of leased space in nine countries in North America, Africa, Europe, Asia, and Australia.

The rest of Item 2

As of December 31, 2025, our Reconstructive segment had a total of four facilities used in production, distribution and warehousing in the U.S., representing a total of 213,000 square feet of leased space, and four facilities used in production, distribution and warehousing outside the U.S., representing a total of 268,000 and 18,000 square feet of owned and leased space, respectively, in three countries in Europe.

Item 2 of the 10-K filed Feb 26, 2026.17

The story

Founded by Mitchell Rales in 1995.1

The company was founded in 1995 as the Colfax Corporation in Richmond, Virginia, by brothers Steven and Mitchell Rales. In August 1997, Colfax acquired approximately 93% of IMO's common stock through a public tender offer. At the time of the acquisition, IMO was a diversified industrial manufacturer, with $469.0 million in annual revenue and five business units: Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Simultaneously with the closing of the tender offer, IMO divested its Gems Sensors and Roltra Morse units to narrow the strategic focus to power transmission and fluid handling.

In January 2012, Colfax completed the acquisition of Charter International, successor to the British South Africa Company, and the parent company of ESAB (welding and cutting) and Howden (air and gas handling products), for $2.4 billion. More than 25 acquisitions were completed from 2012–2019 to build-out the three industrial businesses, fluid handling, fabrication technologies (ESAB), and air & gas handling (Howden).

In December 2017, Colfax sold its original fluid handling platform to Circor International for cash and stock with a total estimated aggregate consideration of $860 million. In November 2018, Colfax expanded into the medical device space by acquiring DJO Global from The Blackstone Group for $3.15bn. In May 2019, KPS Capital Partners (KPS) announced that it has signed an agreement to acquire Howden Turbo from Colfax Corporation for $1.8bn.

In March 2021, Colfax announced that it would spin off its ESAB industrial business in a tax-efficient manner and pursue a focused medical technologies strategy. This spin-off was completed in April 2022, following which ESAB became an independent public company and Colfax was renamed Enovis. The spin-off was the final action taken to transform the portfolio of businesses from purely industrial to medical technologies. These actions included divesting the fluid handling and air and gas handling businesses in 2017 and 2019, respectively, and acquiring DJO Global in 2019. Additional acquisitions were made, and Colfax went public with an initial public offering in May 2008 as a fluid handling company. The headquarters were subsequently moved to Annapolis Junction, Maryland.

In September 2023, Enovis announced that it had reached a definitive agreement to acquire the Villanova di San Daniele del Friuli-headquartered medical device company LimaCorporate for approximately €800 million. On January 3, 2024, it was reported that the purchase of LimaCorporate had been completed.

From Wikipedia’s article on Enovis, shared under CC BY-SA 4.0.6

Leadership

Who has led Colfax Corporation, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (46)

Subsidiaries and ownership

Subsidiaries

Also consolidated

Subsidiaries (Exhibit 21)

  • Armac, Inc. New Jersey7
  • Athena Finance Limited Barbados7
  • Cefar-Compex Medical AB Sweden7
  • Chattanooga Europe, B.V. Belgium7
  • Colfax (Wuxi) Pump Company Limited China7
  • Colfax Group GmbH Germany7
  • DJ Orthopedics Services, SA de CV Mexico7
  • DJ Orthopedics de Mexico, S.A. de C.V. Mexico7
  • DJO Asia-Pacific Ltd. Hong Kong7
  • DJO Benelux B.V. Belgium7
  • DJO Brasil Ltda. Brazil7
  • DJO Canada Inc. Canada7
  • DJO Consumer, LLC Delaware7
  • DJO Finance LLC Delaware7
  • DJO France S.A.S. France7
  • DJO Global India Healthcare Private Limited India7
  • DJO Global Pty Ltd Australia7
  • DJO Global Switzerland SARL Switzerland7
  • DJO Global, Inc. Delaware7
  • DJO Iberica Productos Ortopedicos S.L. Spain7
  • DJO Italia SRL Italy7
  • DJO Medical Device Trading (Shanghai) Ltd. China7
  • DJO Nordic Aktiebolag Sweden7
  • DJO Tunisie SARL Tunisia7
All 86 listed subsidiaries
  • DJO UK Limited United Kingdom7
  • DJO, LLC Delaware7
  • Empi, Inc. Minnesota7
  • Encore Medical GP, LLC Nevada7
  • Encore Medical Partners, LLC Nevada7
  • Encore Medical, L.P. Delaware7
  • Enovis Athena GmbH Switzerland7
  • Enovis Czechia s.r.o. Czech Republic7
  • Enovis Ireland Limited Ireland7
  • Enovis Japan Co., Ltd. Japan7
  • Enovis Korea Co. Ltd. Korea, Republic Of7
  • Enovis Poland SP z.o.o. Poland7
  • Enovis Portugal Sociedade Unipessoal LDA Portugal7
  • Enovis Services, Unipessoal LDA Portugal7
  • Enovis Slovakia s.r.o. Slovakia7
  • Enovis South Africa (Pty) Ltd. South Africa7
  • Enovis Surgical Australia Pty Ltd Australia7
  • Enovis Surgical Austria GmbH Austria7
  • Enovis Surgical Brasil LTDA Brazil7
  • Enovis Surgical Canada, Inc. Canada7
  • Enovis Surgical GB Limited United Kingdom7
  • Enovis Surgical Germany GmbH Germany7
  • Enovis Surgical New Zealand Limited New Zealand7
  • Enovis Surgical Spain Sociedad Limitada Spain7
  • Enovis Surgical Sweden AB Sweden7
  • Enovis Surgical Switzerland GmbH Switzerland7
  • Insight Medical Systems, Inc. Delaware7
  • Kico Knee Innovation Company Pty Limited Australia7
  • LT Technology Ltd China7
  • Lima (Beijing) Medical Devices Co. Ltd. China7
  • Lima Belgium S.p.r.l. Belgium7
  • Lima Denmark A.p.S. Denmark7
  • Lima France SAS France7
  • Lima Netherlands B.V. Netherlands7
  • Lima Orthopaedics Australia Pty Ltd Australia7
  • Lima Orthopaedics South Africa (Pty) Ltd. South Africa7
  • Lima Ortopedija I implantati, d.o.o. Croatia7
  • Lima SM S.p.A San Marino7
  • Lima USA, Inc. Indiana7
  • LimaCorporate S.P.A Italy7
  • LiteCure LLC Delaware7
  • Litecure (Shanghai), LLC China7
  • Litecure Asia Limited Hong Kong7
  • MT Central Finance SARL Switzerland7
  • Mathys AG Bettlach Switzerland7
  • Mathys Orthopaedics BV Netherlands7
  • Mathys Orthopaedics Belux NV Belgium7
  • Mathys Orthopaedics Limited United Kingdom7
  • Mathys Orthopaedie GmbH Germany7
  • Mathys Orthopedie SAS France7
  • Medshape, Inc. Delaware7
  • Mo Milling Pty Limited Australia7
  • Motion Parent, Inc. Delaware7
  • NovaStep Inc. Delaware7
  • NovaStep SAS France7
  • Ormed GmbH Germany7
  • Ortho Pros Express, Inc. North Carolina7
  • Orthomed Medizintechnik GmbH Austria7
  • Precision AI Pty Ltd Australia7
  • Quantum Ops, Inc. Delaware7
  • Surgi-Care, Inc. Massachusetts7
  • Trilliant Surgical, LLC Texas7

From Wikidata.1 Ownership links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); each one cites its LEI record. The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. 2015Acquired Roots Blowers1

Former names

  • Colfax CORPJan 4, 2008 to Mar 18, 20225

Timeline

  1. Sep 1, 20268-K Regulation FD disclosure76
  2. Aug 6, 20268-K Results of operations77
  3. May 19, 20268-K Executive or director change; Shareholder vote78
  4. May 7, 20268-K Results of operations79
  5. Feb 26, 20268-K Results of operations80
  6. Jan 12, 20268-K Regulation FD disclosure81
  7. Dec 15, 20258-K Executive or director change82
  8. Dec 10, 20258-K Entered a material agreement; New debt or obligation83
  9. Nov 14, 20258-K Executive or director change84
  10. Nov 6, 20258-K Results of operations85
  11. Aug 7, 20258-K Results of operations86
  12. May 21, 20258-K Shareholder vote87
  13. May 13, 2025New chief executive Damien McDonald becomes CEO18
  14. Feb 27, 2019New chief executive Brady Shirley becomes CEO19
  15. Jul 27, 2015New chief executive Matthew L. Trerotola becomes CEO20
  16. Jul 28, 2014New chief executive Darryl Mayhorn becomes CEO21
  17. Apr 24, 2012New chief executive Steve Simms becomes CEO23
  18. Feb 24, 2012New chief executive Ian Brander becomes CEO22
  19. Jan 12, 2010New chief executive Clay Kiefaber becomes CEO24
  20. 1995Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.75 a share, on Nov 6, 2025.88

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results77
  2. May 7, 2026Reported quarterly or annual results79
  3. Feb 26, 2026Reported quarterly or annual results80
  4. Nov 6, 2025Reported quarterly or annual results85
  5. Aug 7, 2025Reported quarterly or annual results86
  6. May 8, 2025Reported quarterly or annual results89
  7. Feb 26, 2025Reported quarterly or annual results90
  8. Nov 6, 2024Reported quarterly or annual results91

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

453 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 61 major events, 289 insider forms, 43 large holders, 40 other. The latest 20:

  1. Oct 1, 20264 EDGAR
  2. Sep 8, 20264 EDGAR
  3. Sep 4, 20264 EDGAR
  4. Sep 4, 20264 EDGAR
  5. Sep 1, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G EDGAR
  7. Aug 6, 202610-Q EDGAR
  8. Aug 6, 20268-K EDGAR
  9. Jul 28, 2026SCHEDULE 13G/A EDGAR
  10. Jul 8, 2026SCHEDULE 13G/A EDGAR
  11. Jul 1, 20264 EDGAR
  12. Jun 26, 202611-K EDGAR
  13. Jun 16, 20264 EDGAR
  14. Jun 16, 20264/A EDGAR
  15. Jun 15, 20264 EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 3, 20264 EDGAR
  18. May 28, 2026SD EDGAR
  19. May 21, 20264 EDGAR
  20. May 21, 20264 EDGAR

The 453 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

93 open-market trades by officers, directors and large owners since October 2021: 20 buys and 73 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 4, 2026Engert OliverChief Administrative OfficerBuy2,660$18.80$50.0KForm 4
Sep 4, 2026McDonald DamienChief Executive OfficerBuy13,035$19.15$249.6KForm 4
Sep 3, 2026Engert OliverChief Administrative OfficerBuy5,140$19.46$100.0KForm 4
Sep 2, 2026Engert OliverChief Administrative OfficerBuy2,458$20.32$49.9KForm 4
Jun 15, 2026Engert OliverChief Administrative OfficerBuy1,000$20.92$20.9KForm 4
Jun 11, 2026Engert OliverChief Administrative OfficerBuy1,200$21.62$25.9KForm 4
Jun 10, 2026Engert OliverChief Administrative OfficerBuy1,000$23.00$23.0KForm 4
Jun 1, 2026Engert OliverChief Administrative OfficerBuy1,000$22.22$22.2KForm 4
Mar 13, 2026Engert OliverChief Administrative OfficerBuy1,000$23.74$23.7KForm 4
Mar 10, 2026Engert OliverChief Administrative OfficerBuy1,000$23.93$23.9KForm 4
Mar 9, 2026Engert OliverChief Administrative OfficerBuy1,000$23.39$23.4KForm 4
Mar 6, 2026Engert OliverChief Administrative OfficerBuy750$24.41$18.3KForm 4
Mar 4, 2026Engert OliverChief Administrative OfficerBuy250$25.10$6.3KForm 4
Mar 3, 2026Engert OliverChief Administrative OfficerBuy1,000$24.77$24.8KForm 4
Feb 27, 2026Engert OliverChief Administrative OfficerBuy1,000$25.50$25.5KForm 4
Dec 9, 2025PRYOR DANIEL ASale1,665$27.21$45.3KForm 4
Nov 25, 2025KLECKNER JOHNPrincipal Accounting OfficerBuy2,468$30.32$74.8KForm 4
Sep 11, 2025McDonald DamienChief Executive OfficerBuy6,457$30.97$200.0KForm 4
Aug 22, 2025Tandy Bradley JSVP and Chief Legal OfficerBuy3,200$31.41$100.5KForm 4
Aug 20, 2025BERRY PHILLIP BENJAMIN (BEN)SVP, Chief Financial OfficerBuy2,500$29.71$74.3KForm 4

All 93 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Matthew L. Trerotola$857.5K$9.4M107
2025Damien McDonald61$634.6K$9.2M107
2025Phillip “Ben” Berry$604.9K$5.1M107
2025Daniel A. Pryor$614.9K$3.0M107
2025Terry Ross$514.9K$2.4M107
2025Patricia Lang$502.5K$2.1M107
2025Louis Vogt$500.0K$2.0M107
2024Executive Advisor – former Chief Executive Officer$1.1M$12.5M107
2024Former Executive Vice PresidentStrategy and Business Development$594.8K$3.5M107
2024Chief Financial Officer$586.2K$3.4M107
2024Senior VicePresident and Chief Human Resources Officer$492.5K$2.3M107
2023Executive Advisor – former Chief Executive Officer$1.1M$10.8M107
2023Former Executive Vice PresidentStrategy and Business Development$579.0K$4.8M107
2023Chief Financial Officer$531.4K$2.4M107
2023Senior VicePresident and Chief Human Resources Officer$485.0K$2.1M107

SEC filer profile

How Colfax Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAREnovis CORP2
  • CIK0001420800
  • Employer ID (EIN)54-188763117
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address2900 Lake Vista Drive, Suite 200, Lewisville, TX 750672
  • Phone(302) 252-91602
  • Shares outstanding57,669,494 as of Jul 31, 202615
  • Public float$1.9B as of Jul 4, 202517
  • AuditorErnst & Young LLP, Philadelphia, Pennsylvania PCAOB ID 42; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceJan 4, 20082
  • Filings1,667 in all: 4 (947), 8-K (226), SC 13G/A (77), 3 (63), 10-Q (56), SC 13G (29), UPLOAD (25), DEFA14A (20)2
    All 46 form types

    DEF 14A (19), 10-K (18), CORRESP (17), 11-K (15), 5 (15), 4/A (13), SD (13), 424B5 (11), SCHEDULE 13G/A (11), S-8 (9), SC 13D/A (9), 424B7 (8), FWP (8), SCHEDULE 13G (7), S-1/A (6), S-3ASR (5), 144 (4), 8-K/A (4), ARS (4), IRANNOTICE (4), 425 (3), 10-Q/A (2), 8-A12B (2), PRE 14A (2), PRER14A (2), 10-K/A (1), 25-NSE (1), 305B2 (1), 424B4 (1), CERT (1), CERTNYS (1), D (1), DEFM14A (1), EFFECT (1), NT 10-Q (1), PREM14A (1), S-1 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Feb 26, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 6, 2026
    Latest 8-K (8-K) Sep 1, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareENOVNew York Stock Exchange

From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks Colfax Corporation names in Item 1A of its 10-K filed Feb 26, 2026: 42 risks under these headings, as written.17

  • Risks Related to Our Business and Operations
  • Acquisitions have formed a significant part of our growth strategy. If we are unable to identify suitable acquisition candidates, complete any proposed acquisitions or successfully integrate the businesses we acquire, our growth strategy may not succeed and we may not realize the anticipated benefits of our acquisitions.
  • We may require additional capital to finance our operating needs and to finance our growth. If the terms on which the additional capital is available are unsatisfactory, if the additional capital is not available at all or if we are not able to fully access credit under our Credit Agreement, we may not be able to pursue our growth strategy.
  • Our indebtedness could adversely affect our financial condition and restricts us in ways that limit our flexibility in operating our business.
  • Our restructuring activities may subject us to additional uncertainty in our operating results.
  • Any further impairment in the value of our intangible assets, including Goodwill, would negatively affect our operating results and total capitalization.
  • A material disruption at any of our manufacturing facilities could adversely affect our ability to generate sales and meet customer demand.
  • Failure to maintain and protect our intellectual property rights or challenges to these rights by third parties may affect our operations and financial performance.
  • Risks relating to contagious diseases, terrorist activity, man-made or natural disasters and war have adversely impacted, and may, either alone or in combination with other risks, in the future have an adverse effect on our results of operations, financial condition, and business.
  • Significant movements in foreign currency exchange rates may harm our financial results.
  • We are dependent on the availability of raw materials, as well as parts and components used in our products.
  • We are vulnerable to raw material, energy and labor price fluctuations and supply shortages, which have impacted and could continue to impact our results of operations, financial condition and cash flows.
The other 31 risks
  • The markets we serve are highly competitive and some of our competitors may have superior resources. If we are unable to respond successfully to this competition, this could reduce our sales and operating margins.
  • Changes in our tax rates or exposure to additional income tax liabilities could adversely affect our financial results.
  • We rely on a variety of distribution methods to market and sell our medical device products and if we fail to effectively manage the distribution of such products, our results of operations and future growth could be adversely impacted.
  • Risks Related to Government Regulation and Litigation
  • Our products and our operations are subject to extensive government regulation and oversight, and if we fail to maintain regulatory approvals and clearances, or are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals or their foreign equivalent for our current and future products or product enhancements, our ability to commercially distribute and market these products could suffer.
  • Tariffs and other trade measures could adversely affect our business, results of operations, financial position and cash flows.
  • Modifications to our products may require new regulatory clearances or approvals in the United States and EU or may require us to recall or cease marketing our products until clearances or approvals are obtained.
  • The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us, and failure to report adverse medical events or failures or malfunctions to the FDA as required would subject us to sanctions that could harm our reputation, business, financial condition and results of operations.
  • Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations.
  • We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our products.
  • Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute our products after clearance or approval is obtained.
  • The clinical trial process is lengthy and expensive with uncertain outcomes, often requires the enrollment of large numbers of patients, suitable patients may be difficult to identify and recruit, and delays or failures will prevent us from commercializing new or modified products and will adversely affect our business, operating results and prospects.
  • The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.
  • Our failure to comply with U.S. federal, state and foreign governmental regulations, including in the EU and United Kingdom, could lead to the issuance of warning letters or untitled letters, the imposition of injunctions, suspensions or loss of regulatory clearance, certificates or approvals, product recalls, termination of distribution, product seizures, civil penalties, and in extreme cases, criminal sanctions or closure of manufacturing facilities.
  • Our medical device businesses subject us to the possibility of product liability lawsuits, which could harm our business.
  • If coverage and adequate levels of reimbursement from third-party payors for our medical device products are not obtained, healthcare providers and patients may be reluctant to use our medical device products, our margins may suffer and revenue and profits may decline.
  • Audits or denials of claims by government agencies could reduce our revenues or profits.
  • Federal and state health reform and cost control efforts could adversely impact our business and results of operations, and federal and state legislatures and agencies continue to consider further reforms and cost control efforts that could adversely impact our business and results of operations.
  • Our relationships with customers, physicians and third-party payors are subject to federal and state health care fraud and abuse laws, false claims laws, physician payment transparency laws and other health care laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, or vendors violate these laws we could face substantial penalties.
  • The success of our surgical implant products depends on our relationships with leading surgeons who assist with the development and testing of our products, and our ability to comply with enhanced disclosure requirements regarding payments to physicians.
  • Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations and financial condition.
  • Our information technology infrastructure and information are vulnerable to service interruptions, data corruption, cyber-based attacks, or network security breaches.
  • Our use of artificial intelligence and machine‑learning technologies may expose us to operational, regulatory, and reputational risks.
  • We are subject to anti-bribery laws such as the U.S. Foreign Corrupt Practices Act as well as export controls, economic sanctions, and other trade laws, the violation of which could lead to serious adverse consequences.
  • The risk of non-compliance with non-U.S. laws, regulations and policies could adversely affect our results of operations, financial condition or strategic objectives.
  • Risks Related to the Separation
  • We could incur significant liability if the separation and distribution of ESAB Corporation is determined to be a taxable transaction.
  • Potential indemnification liabilities to ESAB pursuant to the separation agreement could materially and adversely affect our businesses, financial condition, results of operations and cash flows.
  • General Risk Factors and Other Risks
  • Changes in the general economy could negatively impact the demand for our products and services and harm our operations and financial performance.
  • Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the armed conflicts between Russia and Ukraine and in the Middle East.
  • The loss of key leadership or the inability to attract, develop, engage, and retain qualified employees could have a material adverse effect on our ability to run our business.
  • The issuances of additional common and preferred stock may adversely affect the market price of our Common stock.
  • Provisions in our governing documents and Delaware law may delay or prevent an acquisition of Enovis that may be beneficial to our stockholders.

Legal proceedings

Discussion of legal matters is incorporated by reference to Part II, Item 8, Note 18, “Commitments and Contingencies,” in the Notes to the Consolidated Financial Statements.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107